IDEAYA Biosciences Files 8-K on Shareholder Vote Matters
Ticker: IDYA · Form: 8-K · Filed: May 31, 2024 · CIK: 1676725
| Field | Detail |
|---|---|
| Company | Ideaya Biosciences, Inc. (IDYA) |
| Form Type | 8-K |
| Filed Date | May 31, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, shareholder-vote
TL;DR
IDEAYA filed an 8-K for a shareholder vote. Details TBD.
AI Summary
IDEAYA Biosciences, Inc. filed an 8-K on May 31, 2024, to report on matters submitted to a vote of its security holders. The filing does not contain specific details about the proposals or outcomes of the vote, but it is a standard procedural filing.
Why It Matters
This filing indicates that IDEAYA Biosciences held a shareholder vote, which is a routine corporate governance event. The specifics of the vote's outcome could be relevant for understanding shareholder sentiment and company direction.
Risk Assessment
Risk Level: low — This is a routine procedural filing regarding a shareholder vote, not indicating any immediate operational or financial risks.
Key Players & Entities
- IDEAYA Biosciences, Inc. (company) — Registrant
- May 31, 2024 (date) — Date of earliest event reported
FAQ
What specific matters were submitted for a vote of IDEAYA Biosciences' security holders?
The filing does not specify the exact matters submitted for a vote, only that such matters were presented.
When was the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is May 31, 2024.
What is the Commission File Number for IDEAYA Biosciences, Inc.?
The Commission File Number for IDEAYA Biosciences, Inc. is 001-38915.
What is the principal executive office address for IDEAYA Biosciences, Inc.?
The principal executive offices are located at 7000 Shoreline Court, Suite 350, South San Francisco, California 94080.
Under which section of the Securities Exchange Act is this 8-K filed?
This Form 8-K is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Stats: 663 words · 3 min read · ~2 pages · Grade level 12.6 · Accepted 2024-05-31 16:54:31
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share IDYA The Nasdaq
Filing Documents
- idya-20240531.htm (8-K) — 66KB
- 0000950170-24-067407.txt ( ) — 184KB
- idya-20240531.xsd (EX-101.SCH) — 28KB
- idya-20240531_htm.xml (XML) — 5KB
07 Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders. On May 31, 2024, IDEAYA Biosciences, Inc. (the "Company") held its 2024 Annual Meeting of Stockholders (the "Annual Meeting"). At the Annual Meeting, the Company's stockholders voted on four proposals, each of which is described in more detail in the Company's definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 19, 2024. Only stockholders of record as of the close of business on April 4, 2024, the record date for the Annual Meeting, were entitled to vote at the Annual Meeting. As of the record date, 74,764,628 shares of the Company's common stock were outstanding and entitled to vote at the Annual Meeting. The tabulation of the stockholder votes on each proposal brought before the Annual Meeting is as follows: Proposal 1. The election of two Class II directors to hold office until the 2027 annual meeting of stockholders or until their respective successors are elected: Nominee Votes For Votes Withheld Broker Non-Votes Terry J. Rosen, Ph.D. 54,533,987 14,635,187 1,769,710 Wendy L. Yarno 64,201,258 4,521,762 2,215,864 Proposal 2 . The ratification of the selection, by the Audit Committee of the Board of Directors of the Company, of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for the year ending December 31, 2024: Votes For Votes Against Abstentions 70,923,175 6,295 9,414 As a routine proposal under applicable rules, no broker non-votes were recorded in connection with this proposal. Proposal 3 . The non-binding, advisory vote to approve the compensation of the Company's named executive officers: Votes For Votes Against Abstentions Broker Non-Votes 62,946,692 4,602,338 1,646,579 1,743,275 Proposal 4 . The non-binding, advisory vote on the frequency of future advisory votes by stockholders on the compensation of the Company's named executive of
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IDEAYA BIOSCIENCES, INC. Date: May 31, 2024 By: /s/ Yujiro Hata Yujiro Hata President and Chief Executive Officer |||